Drug Profile
Capsaicin - Centrexion Therapeutics
Alternative Names: Adlea; ALGRX-4975; CNTX-4975; CNTX-4975-05; trans-capsaicin; VLNX-4975Latest Information Update: 01 Jan 2024
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer Anesiva; Centrexion Therapeutics
- Class Analgesics; Antipruritics; Catechols; Local anaesthetics; Monounsaturated fatty acids; Non-opioid analgesics; Polyunsaturated alkamides; Small molecules
- Mechanism of Action GABA A receptor modulators; Melatonin receptor modulators; Substance P inhibitors; TRPV1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Pain
- Phase II Neuropathic pain
- Discontinued Postoperative pain
Most Recent Events
- 10 Nov 2023 Pooled efficacy results from the phase III VICTORY-2 and VICTORY-1 trial were presented at the ACR Convergence 2023 (ACR-2023)
- 10 Nov 2023 Efficacy and adverse events data from the phase III VICTORY-1 trial in Pain presented at the ACR Convergence 2023 (ACR-2023)
- 10 Nov 2023 Efficacy and adverse events data from the phase III VICTORY-1 trial in Pain presented at the ACR Convergence 2023 (ACR-2023)